Mipomersen, an Antisense Oligonucleotide to Apolipoprotein B-100, Reduces Lipoprotein(a) in Various Populations With Hypercholesterolemia | Zendy

Raúl D. Santos | Zendy; Frederick J. Raal | Zendy; Alberico L. Catapano | Zendy; Joseph L. Witztum | Zendy; Elisabeth SteinhagenThiessen | Zendy; Sotirios Tsimikas | Zendy

Open Access

Mipomersen, an Antisense Oligonucleotide to Apolipoprotein B-100, Reduces Lipoprotein(a) in Various Populations With Hypercholesterolemia

Author(s) -

Raúl D. Santos,

Frederick J. Raal,

Alberico L. Catapano,

Joseph L. Witztum,

Elisabeth SteinhagenThiessen,

Sotirios Tsimikas

Publication year - 2015

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.114.304549

Subject(s) - apolipoprotein b , lipoprotein(a) , lipoprotein , oligonucleotide , biology , apolipoprotein c2 , familial hypercholesterolemia , genetics , medicine , very low density lipoprotein , endocrinology , cholesterol , gene

Lp(a) is an independent, causal, genetic risk factor for cardiovascular disease and aortic stenosis. Current pharmacological lipid-lowering therapies do not optimally lower Lp(a), particularly in patients with familial hypercholesterolemia (FH).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research